您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

SCITEK INTERNATIONAL (H.K.) LIMITED
Email: sciteck.hongkong@gmail.com
 

当前本网站药物产品种数共 8524 处方药 8148 非处方药 269 保健品/医疗用具 107

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 美国药房
产地国家: 美国
所属类别: 造影剂->核磁共振造影剂
处方药:处方药
包装规格: 3.75毫摩尔/15毫升/瓶 10瓶/盒
计价单位:
  点击放大  
生产厂家中文参考译名:
LANTHEUS MEDCL
生产厂家英文名:
LANTHEUS MEDCL
该药品相关信息网址1:
www.ablavar.com/
该药品相关信息网址2:
www.rxlist.com/ablavar-drug.htm
该药品相关信息网址3:
www.drugs.com/availability/generic-ablavar.html
原产地英文商品名:
ABLAVAR 3.75MMOL/15ML/VIAL 10VIALS/BOX
原产地英文药品名:
GADOFOSVESET TRISODIUM
中文参考商品译名:
ABLAVAR 3.75毫摩尔/15毫升/瓶 10瓶/盒
中文参考药品译名:
钆磷维塞三钠
原产地国家批准上市年份:
2008/12/22
英文适应病症1:
MRI contrast agent
临床试验期:
完成
中文适应病症参考翻译1:
核磁共振造影剂
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201271520404435.PDF)的“原文Priscribing Information”为准
---------------------------------------------------------------
 部分中文ABLAVAR处方资料(仅供参考)

ABLAVAR (钆磷维塞三钠(gadofosveset trisodium)) – 以前称MS-325
批准日期:
2008年12月22日

一般描述:钆磷维塞三钠化学式是三钠-{(2-(R)-[(4,4-diphenylcyclohexyl) phosphonooxymethyl]- diethylenetriaminepentaacetato)(aquo) gadolinium(III),相对分子量975.88 g/mol,和经验式C33H40GdN3Na3O15P。
 
适应证:ABLAVAR注射剂是一种基于钆对比剂适用于作为对比剂在磁共振血流成像(MRA)评价成人中主-髂动脉闭塞病(AIOD)有已知或怀疑周围血管病。

剂量和用法:
通过静脉推注给予ABLAVAR 注射剂,手工或通过功注射,剂量0.12 mL/kg体重(0.03 mmol/kg) 时间至30秒接着25-30 mL生理盐水冲洗。
成像在两个阶段,动力阶段在注射VASOVIST注射剂后立即;一般注射ABLAVAR注射剂后5至7分钟。

剂型和规格:
每mL ABLAVAR注射剂含244 mg钆磷维塞三钠(等同于0.25 mmol/mL)和在单次使用小瓶中。

禁忌证:既往对基于钆对比剂过敏反应史。

警告和注意事项:
某些患者给予基于钆对比剂可能导致肾源性系统纤维化。
来自ABLAVAR给药可能导致超敏反应,包括过敏样和或过敏反应。评估患者对基于钆对比剂过敏史和严密监查患者心脏呼吸急救所需的支持。
基于钆对比剂,包括ABLAVAR在肾功能不全患者中可能增加急性肾衰的风险。
在ABLAVAR 给药后曾报道QTc延长,评估患者有潜在情况史由于QTc延长可能叠加至心律失常

不良反应:最常见(>2%)不良反应是瘙痒、头痛、恶心、血管扩张和感觉异常。

黑框警告:肾源性系统纤维化(NSF)
基于钆的造影剂增加肾源性系统纤维化(NSF)风险。
在急性或慢性严重肾功能障碍患者中(肾小球过滤率 <30 mL/min/1.73m2),
或由于肝肾综合征或在肝移植围手术期任何严重程度的急性肾功能障碍,
在这些患者中,避免使用钆的造影剂除非诊断信息是必不可少的和用无对比剂增强磁共振成像(MRI)不能得到。NSF可能导致死亡或使衰弱的系统性纤维化影响皮肤、肌肉和内脏器官。筛选所有患者肾功能失调通过获得病史和/或实验室检验,当给予某种钆的造影剂,不要超过推荐剂量而且任何再给药前要有充分时间从体内消除药物。

INDICATIONS:
ABLAVAR® is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease.

CONTRAINDICATIONS:
History of a prior allergic reaction to a gadolinium-based contrast agent.

IMPORTANT SAFETY INFORMATION:
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)
Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.  Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.
The risk for NSF appears highest among patients with:
chronic, severe kidney disease (GFR < 30 mL/min/1.73m2), or
acute kidney injury.
Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.
For patients at highest risk for NSF, do not exceed the recommended ABLAVAR dose and allow a sufficient period of time for elimination of the drug from the body prior to re-administration.

ABLAVAR® Injection:  As with other contrast media, the possibility of serious or life-threatening anaphylactic or anaphylactoid reactions, including cardiovascular, respiratory and/or cutaneous manifestations, should always be considered.  As with other gadolinium based contrast agents, caution should be exercised in patients with renal insufficiency due to the possibility of further deterioration in renal function.

In clinical trials, a small increase (2.8 msec) in the average change from baseline in QTc was observed at 45 minutes following ABLAVAR® administration. These QTc prolongations were not associated with arrhythmias or symptoms. Caution should be used in patients at high risk for arrhythmias due to baseline QTc prolongation.

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201271520404435.PDF)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 2012-7-16
附件:
 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:sciteck.hongkong@gmail.com, 15901965168@163.com